ASCO GU 2017 Prostate Cancer - Results from #21

Viewing 22-41 of 43 articles

ASCO GU 2017: Effects of Radium-223 with Docetaxel vs. Docetaxel alone on Bone Biomarkers in Patients with Bone-Metastatic Castration Resistant Prostate Cancer mCRPC: A Phase I/IIa Clinical Trial - Poster Session Highlights

ASCO GU 2017: Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy. - Poster Session Highlights

ASCO GU 2017: Targeting reciprocal feed back inhibition: Apalutamide and everolimus in patients with metastatic castrate resistant prostate cancer - Poster Session Highlights

ASCO GU 2017: Association of changes in circulating cell-free plasma DNA and circulating tumor cells during treatment with clinical outcome from Olaparib in CRPC: exploratory analyses from the TOPARP-A trial

ASCO GU 2017: The utility of Imaging In challenging Cases with High Risk, Recurrent, and Advanced Prostate Cancer - Radiologist - Session Highlights

ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Radiation Oncologist - Session Highlights

ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Medical Oncologist - Session Highlights

ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Surgeon - Session Highlights

ASCO GU 2017: Keynote Lecture: Immunology of Prostate Cancer - Session Highlights

ASCO GU 2017: Clinical significance of AR mRNA quantification from circulating tumor cells in men with metastatic castrate resistant prostate cancer treated with abiraterone or enzalutamide - Session Highlights

ASCO GU 2017: Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens - Session Highlights

ASCO GU 2017: Luminal and basal subtyping of prostate cancer. - Session Highlights

ASCO GU 2017: Advances in the Understanding and Treatment of Androgen-Receptor-Indifferent Prostate Cancer - Session Highlights

ASCO GU 2017: Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. - Session Highlights

ASCO GU 2017: The long tail of significantly mutated genes in prostate cancer - Session Highlights

ASCO GU 2017: Genomic Evolution in Primary and Therapy-Resistant Prostate Cancer - Session Highlights

ASCO GU 2017: Using Liquid Biopsies to Interrogate Circulating Tumor Clone Dynamics and Prostate - Session Highlights

ASCO GU 2017: Prostate cancer meta-analysis from more than 145,000 men to identify 65 novel prostate cancer susceptibility loci - Session Highlights

ASCO GU 2017: Genomic Tests in Active Surveillance and the Role of Hereditary Testing - Session Highlights

ASCO GU 2017: Imaging To Guide Active Surveillance - Session Highlights

1
2
3